Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022

Rhea-AI Summary

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the presentation of new preclinical data on PH-894, an innovative therapeutic based on their proprietary self-delivering RNAi platform, at the ASGCT 25th Annual Meeting from May 16-19, 2022. This research focuses on improving the phenotype of HER2-CAR-T cells during expansion. The poster session is scheduled for May 16, 2022, from 5:30 PM - 6:30 PM EDT at the Walter E. Washington Convention Center in Washington, D.C., highlighting the company's advancements in immuno-oncology therapeutics.

Marlborough, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it will present new preclinical data on PH-894 for use in adoptive cell therapy (ACT) at the American Society for Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is being held May 16-19, 2022 in-person in Washington, D.C. and virtually.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Poster Details are as follows:

Title:	Self-Delivering RNAi Targeting BRD4 (PH-894) Improves the Phenotype of HER2-CAR-T Cells During Expansion
Author:	Benjamin Cuiffo, et al.
Abstract Number:	222
Session:	Oligonucleotide Therapeutics I
Session Date and Time:	Monday, May 16, 2022 5:30 PM - 6:30 PM EDT
Location:	Walter E. Washington Convention Center, Hall D

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com 

Investor Contact
Ashley R. Robinson 
LifeSci Advisors
arr@lifesciadvisors.com 

View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-presentation-of-ph-894-data-at-asgct-25th-annual-meeting-2022-301537295.html

SOURCE Phio Pharmaceuticals Corp.

FAQ

What new data will Phio Pharmaceuticals present on May 16, 2022?

Phio Pharmaceuticals will present new preclinical data on PH-894, focusing on its effects on HER2-CAR-T cells during expansion.

When is the ASGCT 25th Annual Meeting?

The ASGCT 25th Annual Meeting is scheduled for May 16-19, 2022.

Where will Phio Pharmaceuticals present their data?

Phio Pharmaceuticals will present their data at the Walter E. Washington Convention Center in Washington, D.C.

What is the significance of PH-894 in Phio Pharmaceuticals' research?

PH-894 is significant as it aims to enhance the phenotype of HER2-CAR-T cells, representing a potential advancement in cancer cell therapy.

What is the focus of Phio Pharmaceuticals' INTASYL platform?

The INTASYL platform focuses on silencing tumor-induced immune suppression to enhance cancer treatment.